J Am Coll Cardiol, 2007; 49:2151-2159, doi:10.1016/j.jacc.2007.01.091 (Published online 17 May 2007). © 2007 by the American College of Cardiology Foundation

This Article Abstract Full Text Full Text (PDF) View Participating Investigators Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Udelson, J. E. Articles by Konstam, M. A. Search for Related Content PubMed Articles by Udelson, J. E. Articles by Konstam, M. A. Related Collections Related Article

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study on the Effect of Oral Tolvaptan on Left Ventricular Dilation and Function in Patients With Heart Failure and Systolic Dysfunction

James E. Udelson, MD^_*,a,_*, Frank A. McGrew, MD, Enrique Flores, MD, Hassan Ibrahim, MD, Stewart Katz, MD^¶, Gregory Koshkarian, MD^||, Terrence O’Brien, MD^_**, Marvin W. Kronenberg, MD, Christopher Zimmer, MD^,b, Cesare Orlandi, MD^,b and Marvin A. Konstam, MD^_*,a

^_* Division of Cardiology, Tufts-New England Medical Center/Tufts University School of Medicine, Boston, Massachusetts
The Stern Cardiovascular Center, Memphis, Tennessee
Georgia Heart Specialists, Covington, Georgia
North Ohio Research Ltd., Sandusky, Ohio
^¶ Yale University School of Medicine, New Haven, Connecticut
^|| Desert Cardiology of Tucson, Tucson, Arizona
^_** Ralph H. Johnson VA Medical Center, Charleston, South Carolina
Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee
Otsuka America Pharmaceutical, Inc., Rockville, Maryland.

View larger version (20K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Effect of TLV on Time to Death or Heart Failure Hospitalization Time-to-event analysis evaluating patients randomized to tolvaptan (TLV) (red line) versus placebo (PLC) (blue line) with regard to death or hospitalization for worsening heart failure. There was a favorable effect of TLV on this combined end point.

View larger version (20K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Effect of Tolvaptan and Placebo on VP Levels During the Course of the Trial Histogram of changes in vasopressin (VP) levels from baseline to week 54 (in pg/ml) for patients randomized to tolvaptan (open bars) or to placebo (cross-hatched bars). Group changes were significant (Table 7). The histogram of the changes in individual patients shows a shift to the right, which is consistent with the significant increase in the patients randomized to tolvaptan, as shown in Table 7.